| Margins | EBITDA margins improved YoY from 38.1% to 39.6%. |
|---|---|
| Demand visibility | Strong, with scheduled deliveries concentrated in H2 FY27. |
| Management confidence | High; citing strong underlying demand and historical alignment. |
Growth
Revenue fell 22.6% YoY to ₹4,182 Mn; PAT decreased 11.7% YoY to ₹1,199 Mn.
Outlook
Positioned to capture momentum in H2; maintenance of industry-leading margin profile via cost efficiencies.
Risks
Timing shifts in deliveries to key customers impacted Q1 performance; dependency on second-half concentration.
Last quarter's promises, checked
Delivered
- Guided 20% historical growth → delivered 18% FY26 revenue growth (= BEAT)
- Guided 30% EBITDA growth → delivered 31% FY26 EBITDA growth (= BEAT)
- Guided 30% PAT growth → delivered 31% FY26 PAT growth (= BEAT)
Partly delivered
- Guided 38-40% EBITDA margins → delivered 39.6% in Q1FY27 (= PARTIAL)
Missed
- Guided Q1FY27 momentum → delivered -22.6% YoY revenue growth (= MISS)
Investor Presentation filed with NSE, NSE: ANTHEM. Summary written with AI assistance from the document.
Anthem Biosciences Ltd: key numbers
- Share price
- ₹890.35
- Market cap
- ₹50,144 Cr
- Revenue (annual)
- ₹2,124 Cr
- Net profit (annual)
- ₹591.8 Cr
- P/E (TTM)
- 87.1×Sector 47.4×
- Promoter holding
- 71.42%-3.26% QoQ
- FII holding
- 2.57%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Anthem Biosciences Ltd
All →Anthem Biosciences Other Announcement
Designated Person Viridity Tone LLP sold shares of Anthem Biosciences Ltd worth ₹82.67 Crore via market sale.
- Value
- ₹82.67 Cr
Anthem Biosciences Legal & Regulatory
Anthem Biosciences Ltd announced the settlement of an upside sharing amount of ₹127.68 Crore related to a prior divestment, following shareholder approval.
- Value
- ₹127.7 Cr
Anthem Biosciences Management Change
Anthem Biosciences appointed S.R. Batliboi & Associates LLP as Statutory Auditor and noted director changes, including a rotation and continuation of directorship.
Anthem Biosciences Annual General Meeting
Anthem Biosciences held its 20th AGM on July 22, 2026. Shareholders approved all business resolutions, including financial statements, dividend declaration, and statutory auditor appointments.
Anthem Biosciences Earnings Call Transcript: Key Takeaways
Revenue fell 25% YoY due to deferred deliveries, though management claims a record order book will drive second-half recovery. While EBITDA margins remain high at 39.6%, the quarter reflects high lumpiness in the CRDMO business.
Anthem Biosciences Results Update
Anthem Biosciences reported Q1FY27 revenue of ₹418.2 Crore and profit after tax of ₹119.9 Crore. The company continues its focus on margin improvement and cost efficiencies.